Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies
暂无分享,去创建一个
Wei Xu | Jun Wang | Teng Jiang | Jin-Tai Yu | L. Tan | Huifu Wang | Jun Wang | Lin Tan | Jieqiong Li | W. Xu | Wei Xu | M. Tan | Qing-Fei Zhao | T. Jiang | Jin-Tai Yu | Lan Tan | Lin Tan | Meng-Shan Tan | Jie-Qiong Li | Hui-Fu Wang | Qing-Fei Zhao | Jin-Tai Yu | Teng Jiang
[1] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[2] R. Marin,et al. Apathy: a neuropsychiatric syndrome. , 1991, The Journal of neuropsychiatry and clinical neurosciences.
[3] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[4] Jane S. Paulsen,et al. Apathy is not depression. , 1998, The Journal of neuropsychiatry and clinical neurosciences.
[5] R. Stewart,et al. Type 2 diabetes mellitus, cognitive impairment and dementia , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[6] J. Morris,et al. Current concepts in mild cognitive impairment. , 2001, Archives of neurology.
[7] M. Albert,et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD , 2002, Neurology.
[8] D. A. Bennett,et al. Natural history of mild cognitive impairment in older persons , 2002, Neurology.
[9] H. Xue,et al. GABAergic functions and depression: from classical therapies to herbal medicine. , 2003, Current drug targets. CNS and neurological disorders.
[10] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[11] A. Hofman,et al. Silent brain infarcts and the risk of dementia and cognitive decline. , 2003, The New England journal of medicine.
[12] B. Reisberg,et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease , 2004, Journal of internal medicine.
[13] R. Petersen. Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.
[14] C. Jack,et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.
[15] H. Soininen,et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.
[16] J. Kaye,et al. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline , 2008, Neurology.
[17] H. Soininen,et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.
[18] A. Stang. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.
[19] P. Visser,et al. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[20] C. Huang,et al. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta‐analysis of longitudinal studies , 2012, Internal medicine journal.